SZLSF.US StageZero Life Sciences Ltd
- Market cap
- USD 124K
- P/E
- -
- P/B
- 5.60x
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2024.
Is SZLSF.US undervalued?
Graham numberThe Graham number of StageZero Life Sciences Ltd cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
StageZero Life Sciences Ltd fundamental analysis
No fundamental analysis for StageZero Life Sciences Ltd yet.
StageZero Life Sciences Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About StageZero Life Sciences Ltd
StageZero Life Sciences Ltd., a vertically integrated healthcare company, develops and commercializes proprietary molecular diagnostic tests for the early detection of diseases and personalized health management with a primary focus on cancer-related indications in North America and Western Europe. Its proprietary platform technology is Sentinel Principle, which identifies RNA-based biomarkers from whole blood. The company's lead product is Aristotle, a mRNA-based multi-canc…
Full company profileStageZero Life Sciences Ltd financial statements
2024 annualized: Fiscal year 2024 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2024, the balance sheet is the latest quarter. Figures change when the annual report is published.
StageZero Life Sciences Ltd annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 2.11M | 326K | 1.05M | 412K | 186K | 139K | 4.15M | 5.07M | 3.80M | 2.88M | 1.88M |
| Gross Profit | 2.11M | 326K | -415K | -993K | -1.08M | -961K | 696K | 1.18M | -404K | 10.4K | 292K |
| Operating Income | -6.61M | -6.04M | -4.26M | -3.90M | -4.36M | -5.11M | -3.74M | -7.96M | -7.75M | -4.61M | -1.82M |
| EBITDA | -6.93M | -5.99M | -5.23M | -2.17M | -2.82M | -2.52M | -6.33M | -5.49M | -10.3M | - | -1.62M |
| Net Income | -6.61M | -6.02M | -5.91M | -2.95M | -3.94M | -3.48M | -6.86M | -7.48M | -11.4M | -12.5M | -1.91M |
| EPS | -1.12 | -0.90 | -0.72 | -0.24 | -0.23 | -0.13 | -0.15 | -0.11 | -0.11 | - | -0.02 |
| Balance Sheet | |||||||||||
| Total Assets | 2.93M | 572K | 3.44M | 2.69M | 2.49M | 1.96M | 8.51M | 10.6M | 701K | - | 581K |
| Total Liabilities | 776K | 2.34M | 8.17M | 5.71M | 7.32M | 6.46M | 9.74M | 7.88M | 8.20M | - | 11.7M |
| Shareholders' Equity | 2.15M | -1.77M | -4.73M | -3.02M | -4.84M | -4.49M | -1.23M | 2.76M | -7.50M | - | -11.1M |
| Cash & Short-term Investments | 2.34M | 516K | 214K | 41.2K | 106K | 71.1K | 6.60M | 1.72M | 15.7K | - | 15.0K |
| Total Debt | - | 1.32M | 3.02M | 1.58M | 3.22M | 2.46M | 3.57M | 1.36M | 1.80M | - | 2.13M |
| Cash Flow | |||||||||||
| Operating Cash Flow | -1.54M | -1.73M | -3.68M | -3.82M | -3.29M | -4.59M | -3.06M | -8.95M | -3.53M | -809K | -194K |
| Capital Expenditure | 3.54K | 771.00 | 0.00 | 7.27K | 2.79K | 44.4K | 72.3K | 148K | 2.44 | 0.00 | 8.77 |
| Free Cash Flow | -1.54M | -1.73M | -3.68M | -3.82M | -3.29M | -4.64M | -3.14M | -9.10M | -3.53M | -809K | -194K |
| Ratios | |||||||||||
| ROE | -306.8% | - | - | - | - | - | - | -271.0% | - | - | - |
| ROA | -225.6% | -1,051.6% | -171.7% | -109.4% | -158.7% | -177.2% | -80.7% | -70.3% | -1,629.2% | - | -329.1% |
| Net Profit Margin | -312.9% | -1,846.7% | -560.8% | -716.0% | -2,121.8% | -2,510.2% | -165.3% | -147.7% | -300.8% | -434.8% | -101.7% |
| Debt to Equity | - | - | - | - | - | - | - | 0.49x | - | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
StageZero Life Sciences Ltd dividends
StageZero Life Sciences Ltd has not paid dividends in the last 9 fiscal years.
Last stock split: 1:8 on Sep 18, 2020.
Who owns StageZero Life Sciences Ltd
- Insiders 19.99%
- Institutions 0.00%
- Public & others 80.01%
- Shares outstanding 124M
- Free float 111M
StageZero Life Sciences Ltd company profile
- Company name
- StageZero Life Sciences Ltd
- Ticker
- SZLSF.US
- Exchange
- USA Stocks
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 40
- Fiscal year end
- December
- Address
- 70 East Beaver Creek Road, Richmond Hill, ON, Canada, L4B 3B2
- Website
- stagezerolifesciences.com
About StageZero Life Sciences Ltd
StageZero Life Sciences Ltd., a vertically integrated healthcare company, develops and commercializes proprietary molecular diagnostic tests for the early detection of diseases and personalized health management with a primary focus on cancer-related indications in North America and Western Europe. Its proprietary platform technology is Sentinel Principle, which identifies RNA-based biomarkers from whole blood. The company's lead product is Aristotle, a mRNA-based multi-cancer detection panel that tests blood for multiple discrete cancer. It also offers ColonSentry, a blood-based test to determine an individual's current risk for having colorectal cancer. The company is based in Richmond Hill, Canada.
StageZero Life Sciences Ltd management
2- Mr. James R. Howard-TrippExecutive Chairman & CEO
- Mr. Warren Whitehead C.M.A., CPAChief Accountant · born 1952